GSK has agreed to buy U.S.-listed cancer drug developer Nuvalent for $10.6 billion in its largest deal in more than a decade, marking a strategic shift under new CEO ‌Luke Miels as the British. GSK agreed to buy U.S. cancer-drug developer Nuvalent for $10.6 billion, the British pharmaceutical company’s latest move to bolster its oncology business. The homepage of the GSK USA website June is Uterine Cancer Awareness Month Endometrial cancer is the most common type of uterine cancer, and its symptoms are never something to be embarrassed about. Learn more about signs to watch out for and when to speak up, because your health is too important to keep quiet about. GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that could challenge products from Roche, Pfizer and other drugmakers. GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year U.K. pharmaceutical group GSK has entered an agreement to acquire U.S.-based specialist oncology biotech Nuvalent for $10.6 billion. The acquisition could help GSK offset a drop in revenue. GSK Boosts Cancer Portfolio With $10.6 Billion Nuvalent Takeover By Bhanvi Satija and Yadarisa Shabong LONDON, June 9 (Reuters) - GSK has agreed to buy U.S.-listed cancer ⁠drug ⁠developer. At GSK, we unite science, technology and talent to get ahead of disease together GSK PLC (LSE:GSK, NYSE:GSK) shares fell 3% after it agreed to acquire US biotechnology company Nuvalent (NASDAQ:NUVL) for $10.6 billion (£8.0 billion), adding immediate new revenues and a trio of. GSK plc (an abbreviation of its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company. [3][4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.